CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
QuickLinks -- Click here to rapidly navigate through this document
REDACTED VERSION
[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS.
December 20, 2002
▇▇. ▇▇▇▇
▇▇▇▇▇▇▇
President and Chief Executive Officer
Schering Berlin Inc.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇
▇.▇. ▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
Fax: ▇▇▇.▇▇▇.▇▇▇▇
- Re:
- Regulatory
Filing, Development and Supply Agreement dated May 10, 1993
between Chiron Corporation and Schering AG (the "RFDS Agreement")
Dear ▇▇▇▇:
This is to confirm our understanding with respect to cost-sharing for the diluent syringe:
Chiron and Schering have agreed to proceed with a diluent syringe for Betaseron®. In connection therewith, Chiron has negotiated agreements with ▇▇▇▇▇▇ for diluent syringe filling, MedNet for the vial adapter component, and PCI for diluent syringe packaging, the key terms of which are set out in an attachment to this letter. Schering and Chiron have agreed to share the incremental costs of the diluent syringe under such agreements as follows: in the event Schering and Chiron sign a new agreement replacing the RFDS Agreement, [***] Schering, [***] Chiron; in the event the parties do not sign such a new agreement, Chiron's share will equal [***] and Schering's share shall [***].
Please sign the enclosed copy of this letter for our records.
Very truly yours,
CHIRON CORPORATION
| By: | /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇ President, Chiron BioPharmaceuticals |
|||||
Agreed: |
||||||
SCHERING BERLIN, INC. |
||||||
By: |
/s/ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ |
|||||
| [Signed copy shows strike-through of this name: ▇▇▇▇ ▇▇▇▇▇▇▇] ▇. ▇▇▇▇▇ EVP and CFO |
||||||